ING Bank Slaski S.A. (6GF)
Market Closed
3 Dec, 07:04
XMUN 
€
77. 80
0
0%
€
- Market Cap
- P/E Ratio
0% Div Yield
0 Volume
- Eps
€ 77.8
Previous Close Day Range
77.8 77.8
Year Range
56.5 83.3
Want to track 6GF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 54 days
Summary
6GF closed Wednesday higher at €77.8, an increase of 0% from Tuesday's close, completing a monthly decrease of -6.38% or €5.3. Over the past 12 months, 6GF stock gained 36.49%.
6GF is not paying dividends to its shareholders.
The last earnings report, released on Oct 30, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports. The next scheduled earnings report is due on Feb 05, 2026.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on XFRA (EUR).
6GF Chart
ING Bank Slaski S.A. (6GF) FAQ
What is the stock price today?
The current price is €77.80.
On which exchange is it traded?
ING Bank Slaski S.A. is listed on XFRA.
What is its stock symbol?
The ticker symbol is 6GF.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0%.
What is its market cap?
As of today, no market cap data is available.
When is the next earnings date?
The next earnings report will release on Feb 05, 2026.
Has ING Bank Slaski S.A. ever had a stock split?
No, there has never been a stock split.
ING Bank Slaski S.A. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | - CEO | XMUN Exchange | PLBSK0000017 ISIN |
| Germany Country | - Employees | 5 May 2025 Last Dividend | - Last Split | - IPO Date |
Overview
Cantourage Group SE is a notable presence in the European medical cannabis market, focusing on the provision of a range of cannabis-based medicinal products. With its inception in 2019, the company has quickly established itself in Kleinmachnow, Germany. Cantourage Group SE is dedicated to ensuring the availability of high-standard cannabis products to meet the growing demands in the pharmaceutical sector, emphasizing quality and therapeutic efficacy.
Products and Services
- Dried Flowers: These are carefully selected cannabis flowers offered for their medicinal properties. The drying process preserves the cannabinoids, terpenes, and other essential compounds, making them suitable for various medical applications, such as pain management, alleviating the symptoms of multiple sclerosis, and reducing nausea during chemotherapy.
- Extracts: Cantourage Group SE provides concentrated cannabis extracts. These extracts contain high levels of cannabinoids and are used in the formulation of medicinal products. They are designed for patients who require precise dosages of THC, CBD, or other cannabinoids, offering a more controlled intake than dried flowers.
- Dronabinol Products: Dronabinol, a synthetic form of THC, is available in several therapeutic formulations. These products aim at treating an assortment of conditions, including but not limited to, appetite loss in AIDS patients and nausea and vomiting caused by cancer chemotherapy. Dronabinol mimics the effects of natural cannabinoids, providing effective symptom relief.
- Pharma-grade Cannabidiol Products: These are pharmaceutical-grade CBD products, distinguished by their purity and quality. They cater to patients needing CBD for its therapeutic benefits without the psychoactive effects of THC. Common uses include treatment for epilepsy, anxiety disorders, and inflammatory diseases. Pharma-grade ensures the highest standard for safety and efficacy.
Contact Information
Address: Heinrich-Mann-Str. 12
Phone: 49 30 4701 350 50
Website: https://www.cantourage.com
2025 © Marketlog. All Rights Reserved.
